Notice NOT-AG-23-032 from the NIH Guide for Grants and Contracts

Notice NOT-CA-23-071 from the NIH Guide for Grants and Contracts

Notice NOT-NR-23-011 from the NIH Guide for Grants and Contracts

Notice NOT-TR-23-024 from the NIH Guide for Grants and Contracts

Notice NOT-NS-23-090 from the NIH Guide for Grants and Contracts

Notice NOT-MD-23-017 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HG-23-027 from the NIH Guide for Grants and Contracts. The Ethical, Legal and Social Implications (ELSI) Research Program of the National Human Genome Research Institute (NHGRI) solicits application for the renewal of the Center for ELSI Resources and Analysis (CERA). Building on work completed during the initial funding period, CERA will: 1) provide ELSI researchers with a stable platform to share ELSI research products related to genomics; 2) curate and synthesize ELSI research; and 3) facilitate new research collaborations and uptake of ELSI research. CERA will increase the availability and visibility of ELSI products and resources and serve as a source of expertise for the larger research and policy communities.

Funding Opportunity RFA-ES-23-009 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support a Chemical Exposure Resource and Coordination Core (ExRC) that will provide infrastructure, management, and research support for studies of Chemicals of Concern (CoC) to the Chemical Countermeasures Research Program (CCRP). This core, established across diverse geographical regions, is intended to support multidisciplinary CCRP investigators, through development of infrastructure and exposure protocols for selected toxicants. The ExRC will provide facility access for using diverse models to characterize pathophysiological mechanisms and evaluating potential medical countermeasures through early-stage development efforts supported by the CCRP.

Notice NOT-CA-23-074 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-141 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HG-23-026 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute (NHGRI) will renew the Human Genome Reference Program (HGRP). This Informatics Tools for the Pangenome FOA will provide multiple awards to develop informatics tools that enable uptake and use of the improved pangenome reference. Emphasis will be on tools for common use cases that are relevant to different broad sectors of the genomics community, e.g., clinical, population, and functional genomics. Possible examples include selecting the best subset of linear genomes or paths along the graph for a given set of samples, visualizing complex variation, and annotating regulatory elements and disease associations.

Funding Opportunity RFA-HG-23-025 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute (NHGRI) will renew the Human Genome Reference Program (HGRP). This FOA will establish the Human Pangenome Coordinating Center (HPCC), the central component of the HGRP. The HPCC will serve as the logistic and scientific coordinating center for the HGRP and will create, improve, release, and maintain new pangenome reference versions. The overall goal of the HGRP during the renewal is to produce a human pangenome reference that optimizes both the population genetic diversity represented, along with the utility for, and adoption by, the genomics research community. This is a limited competition RFA. Only recipient organizations funded under RFA-HG-19-004 are eligible to apply.

Funding Opportunity RFA-HG-23-024 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute (NHGRI) will renew the NHGRI Human Genome Reference Program (HGRP). This FOA seeks applications for the production of High Quality Human Reference Genomes (HQRG) as one of three components of the renewed HGRP. The HQRG component will lead the prioritization and selection of samples from diverse participants consented for open access data release, and, with those samples, produce 200 new, very high-quality haplotype-resolved human genome assemblies for inclusion in the human pangenome reference. The HQRG component will also include a team of ethical, legal and social issues scholars who will be embedded in the overall HGRP. This team will be integrated with the consortium to help identify and navigate topics raised by the development of a human pangenome resource, including consent, data release and sovereignty, definitions of diversity, and others that may arise over time. This is a limited competition RFA. Only recipient organizations funded under RFA-HG-19-002 are eligible to apply.

Notice NOT-GM-23-046 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-195 from the NIH Guide for Grants and Contracts. The ultimate goal is to develop multi-target disease-modifying therapeutics based on an appreciation of the complex interaction of pathways, cells, circuits, systems or pathologies that are present in complex AD/ADRD diagnoses. Such therapeutics could be a single drug or biologic targeting multiple pathways, cell, circuits, systems or pathologies, or could be a combination of therapies. While hundreds of possible targets have been suggested for AD alone, theres a need to better understand how multiple targets might interact in a synergistic way that would allow us to tackle AD/ADRD from multiple fronts in a single person, akin to what has been successful in infectious disease or cancer. This FOA will support applications that test hypotheses of possible beneficial interactions of known targets as well as understanding the mechanisms of interaction in the R61. The R33 would support rigorous validation of the proposed multi-target approach (one drug or biologic targeting multiple pathways; and/or a combination of therapies) to support future multi-target therapy development efforts. Successful grantees will be in position to apply for IGNITE or other similar translational grant mechanisms.

Funding Opportunity RFA-HL-24-011 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to advance hematopoietic cell transplantation (HCT) for all patients, but particularly for patients with rare and difficult to treat non-malignant blood diseases and hematological malignancies. This will be accomplished by supporting a clinical trials network to evaluate novel cell therapy (CT) and HCT approaches. A Data Coordinating Center (DCC) and core clinical sites will be supported by funds requested as part of this initiative, as well as a limited number of trials. Additional studies and trials will be funded through collaborations with RO I-funded grantees, industry, and foundations. Multiple factors extend the duration of most HCT and CT trials beyond 5 years, including rare patient populations (and hence accrual periods of up to 5 years), complex cell manufacturing processes, and composite endpoints such as disease-free survival and chronic graft versus-host disease free survival that occur 2 or more years post-transplant. A seven year program to support these activities is needed.

Funding Opportunity RFA-HL-24-010 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to advance hematopoietic cell transplantation (HCT) for all patients, but particularly for patients with rare and difficult to treat non-malignant blood diseases and hematological malignancies. This will be accomplished by supporting a clinical trials network to evaluate novel cell therapy (CT) and HCT approaches. A Data Coordinating Center (DCC) and core clinical sites will be supported by funds requested as part of this initiative, as well as a limited number of trials. Additional studies and trials will be funded through collaborations with R01-funded grantees, industry, and foundations. Multiple factors extend the duration of most HCT and CT trials beyond 5 years, including rare patient populations (and hence accrual periods of up to 5 years), complex cell manufacturing processes, and composite endpoints such as disease-free survival and chronic graft versus-host disease free survival that occur 2 or more years post-transplant. A seven year program to support these activities is needed.

Funding Opportunity PAR-24-210 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for centers to support transdisciplinary teams of clinical and mental health services researchers, behavioral scientists, social scientists, health information and communications technologists, health systems engineers, decision scientists, and mental health stakeholders (e.g., service users, family members, clinicians, payers) to engage in high-impact studies that will significantly advance clinical practice and generate knowledge that will fuel transformation of mental health care in the United States. Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers will support the rapid development, testing, and refinement of novel and integrative approaches for (1) optimizing the effectiveness of therapeutic or preventive interventions for mental disorders within well-defined target populations; (2) organizing and delivering optimized mental health services within real world treatment settings; and (3) continuously improving the quality, impact, and durability of optimized interventions and service delivery within diverse care systems. The ALACRITY Centers program is intended to support research that maximizes synergies across various components of the mental health research ecosystem, including new discoveries in clinical research, transformative health care technologies, advances in information science, and new federal and state mechanisms for organizing mental health care.

Notice NOT-OD-23-138 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-24-280 from the NIH Guide for Grants and Contracts. The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.